# NCT05707273 (NCT05707273)

> CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05707273
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: City of Hope Medical Center
- Conditions: B Acute Lymphoblastic Leukemia
- Interventions: Autologous Anti-CD19 CAR-expressing T Lymphocytes; Biospecimen Collection; Bone Marrow Aspiration and Biopsy; Cyclophosphamide; Fludarabine; Leukapheresis; Questionnaire Administration
- Enrollment: 18
- Primary outcome: Incidence of dose-limiting toxicity (DLT)
- Primary outcome: Incidence of adverse events

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05707273